セルソースの株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2024/03/05 | 1,375 | 1,403 | 1,370 | 1,379 | -26 | -1.9% | 145,700 |
| 2024/03/04 | 1,421 | 1,427 | 1,358 | 1,405 | -9 | -0.6% | 205,700 |
| 2024/03/01 | 1,364 | 1,430 | 1,364 | 1,414 | +43 | +3.1% | 291,300 |
| 2024/02/29 | 1,359 | 1,378 | 1,321 | 1,371 | +8 | +0.6% | 145,800 |
| 2024/02/28 | 1,346 | 1,377 | 1,341 | 1,363 | +29 | +2.2% | 213,900 |
| 2024/02/27 | 1,345 | 1,361 | 1,316 | 1,334 | +19 | +1.4% | 163,500 |
| 2024/02/26 | 1,224 | 1,334 | 1,203 | 1,315 | +92 | +7.5% | 335,000 |
| 2024/02/22 | 1,242 | 1,250 | 1,202 | 1,223 | -18 | -1.5% | 226,700 |
| 2024/02/21 | 1,317 | 1,317 | 1,241 | 1,241 | -57 | -4.4% | 173,500 |
| 2024/02/20 | 1,328 | 1,330 | 1,289 | 1,298 | -14 | -1.1% | 122,000 |
| 2024/02/19 | 1,248 | 1,323 | 1,241 | 1,312 | +75 | +6.1% | 196,400 |
| 2024/02/16 | 1,197 | 1,252 | 1,196 | 1,237 | +42 | +3.5% | 175,900 |
| 2024/02/15 | 1,250 | 1,250 | 1,193 | 1,195 | -59 | -4.7% | 260,500 |
| 2024/02/14 | 1,265 | 1,268 | 1,235 | 1,254 | -29 | -2.3% | 134,500 |
| 2024/02/13 | 1,279 | 1,314 | 1,277 | 1,283 | +5 | +0.4% | 119,800 |
| 2024/02/09 | 1,299 | 1,303 | 1,270 | 1,278 | -22 | -1.7% | 89,200 |
| 2024/02/08 | 1,296 | 1,313 | 1,272 | 1,300 | -8 | -0.6% | 115,000 |
| 2024/02/07 | 1,315 | 1,344 | 1,281 | 1,308 | -35 | -2.6% | 153,700 |
| 2024/02/06 | 1,363 | 1,364 | 1,316 | 1,343 | -28 | -2% | 177,300 |
| 2024/02/05 | 1,314 | 1,388 | 1,288 | 1,371 | +56 | +4.3% | 247,500 |
| 2024/02/02 | 1,276 | 1,337 | 1,265 | 1,315 | +38 | +3% | 236,500 |
| 2024/02/01 | 1,235 | 1,280 | 1,235 | 1,277 | +28 | +2.2% | 161,400 |
| 2024/01/31 | 1,221 | 1,249 | 1,197 | 1,249 | +28 | +2.3% | 157,900 |
| 2024/01/30 | 1,230 | 1,246 | 1,198 | 1,221 | -9 | -0.7% | 236,700 |
| 2024/01/29 | 1,235 | 1,249 | 1,224 | 1,230 | -8 | -0.6% | 103,200 |
| 2024/01/26 | 1,262 | 1,267 | 1,219 | 1,238 | -27 | -2.1% | 212,500 |
| 2024/01/25 | 1,215 | 1,279 | 1,187 | 1,265 | +50 | +4.1% | 292,500 |
| 2024/01/24 | 1,210 | 1,229 | 1,198 | 1,215 | +21 | +1.8% | 125,300 |
| 2024/01/23 | 1,233 | 1,241 | 1,193 | 1,194 | -15 | -1.2% | 140,400 |
| 2024/01/22 | 1,203 | 1,213 | 1,179 | 1,209 | +3 | +0.2% | 209,200 |
| 2024/01/19 | 1,217 | 1,236 | 1,201 | 1,206 | -16 | -1.3% | 122,600 |
| 2024/01/18 | 1,249 | 1,250 | 1,217 | 1,222 | -18 | -1.5% | 120,900 |
| 2024/01/17 | 1,269 | 1,271 | 1,240 | 1,240 | -52 | -4% | 214,600 |
| 2024/01/16 | 1,314 | 1,331 | 1,290 | 1,292 | -11 | -0.8% | 145,400 |
| 2024/01/15 | 1,282 | 1,308 | 1,260 | 1,303 | +32 | +2.5% | 132,800 |
| 2024/01/12 | 1,274 | 1,278 | 1,240 | 1,271 | -3 | -0.2% | 170,300 |
| 2024/01/11 | 1,280 | 1,282 | 1,254 | 1,274 | +5 | +0.4% | 147,700 |
| 2024/01/10 | 1,286 | 1,308 | 1,268 | 1,269 | -6 | -0.5% | 182,600 |
| 2024/01/09 | 1,278 | 1,300 | 1,258 | 1,275 | ±0 | ±0% | 146,100 |
| 2024/01/05 | 1,301 | 1,306 | 1,270 | 1,275 | -33 | -2.5% | 162,400 |
| 2024/01/04 | 1,252 | 1,308 | 1,230 | 1,308 | +29 | +2.3% | 171,900 |
| 2023/12/29 | 1,266 | 1,300 | 1,258 | 1,279 | -11 | -0.9% | 234,400 |
| 2023/12/28 | 1,240 | 1,290 | 1,201 | 1,290 | +46 | +3.7% | 280,100 |
| 2023/12/27 | 1,187 | 1,267 | 1,184 | 1,244 | +42 | +3.5% | 524,300 |
| 2023/12/26 | 1,235 | 1,258 | 1,200 | 1,202 | -63 | -5% | 519,800 |
| 2023/12/25 | 1,330 | 1,334 | 1,265 | 1,265 | -71 | -5.3% | 432,200 |
| 2023/12/22 | 1,371 | 1,389 | 1,330 | 1,336 | -52 | -3.7% | 237,100 |
| 2023/12/21 | 1,451 | 1,453 | 1,361 | 1,388 | -82 | -5.6% | 357,700 |
| 2023/12/20 | 1,364 | 1,470 | 1,352 | 1,470 | +101 | +7.4% | 474,200 |
| 2023/12/19 | 1,360 | 1,369 | 1,306 | 1,369 | +8 | +0.6% | 448,600 |
51～
100
件表示中 / 1112件
類似銘柄と比較する
現在ご覧いただいている「セルソース」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| セルソース | 141,900円 | +19.0% | -13.1% | 0.35% | 39.09倍 | 4.57倍 |
|
脂肪・血液由来の細胞加工受託など再生医療、変形性ひざ関節症向け軸に不妊治療関連も展開 |
| サンバイオ | 46,300円 | - | - | 0.00% | - | 12.29倍 |
|
脳疾患向け再生細胞薬の開発・製造・販売目指すバイオベンチャー。米国で創業し日本に逆上陸 |
| ステムリム | 46,500円 | -14.9% | -31.0% | 0.00% | 190.57倍 | 3.34倍 |
|
大阪大学発バイオベンチャー。損傷細胞の活性化物質を動員、再生を促す「再生誘導医薬」を開発 |
| クオリプス | 323,000円 | -13.0% | - | 0.00% | - | 4.30倍 |
|
大阪大学発ベンチャー。ｉＰＳ細胞由来のシートによる世界初の重症心不全治療法開発に注力 |
| 扶桑薬 | 228,700円 | +2.9% | +23.1% | 3.50% | 11.50倍 | 0.53倍 |
|
人工腎臓用透析剤・補液が主軸の製薬中堅、透析剤は国内シェア５割。後発薬や製造受託も展開 |
市場注目の銘柄
チャート関連のコラム
